IMARC Group, a leading market research company, has recently releases report titled “Cell and Gene Therapy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033,” The study provides a detailed analysis of the industry, including the global cell and gene therapy market size, share, growth, trends and forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the cell and gene therapy market?

The global cell and gene therapy market size reached US$ 18.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 60.1 Billion by 2032, exhibiting a growth rate (CAGR) of 15.66% during 2024-2032

Factors Affecting the Growth of the Cell and Gene Therapy Industry:

  • Rapid Advances in Biotechnology and Genetic Engineering:

The rapid advancements in biotechnology and genetic engineering that enable scientists to develop treatments that modify or replace genes and use cells as therapeutic agents to address various genetic disorders and diseases are fueling the market growth. Genetic engineering techniques, including clustered regularly interspaced short palindromic repeats (CRISPR), transcription activator-like effector nucleases (TALENs), and zinc finger nucleases that make gene editing more precise, efficient, and cost-effective, are propelling the market growth. Biotechnology advancements enhance the scalability and safety of these therapies. In line with this, the development of viral vectors to deliver therapeutic genes into patients' cells to improve their safety profile and efficiency is fostering the market growth.

  • Rising Regulatory Support and Financial Investment:

The growing regulatory support and substantial financial investments by regulatory agencies across the globe to establish clearer pathways for the approval of therapies are catalyzing the market growth. In line with this, the increasing financial investment in cell and gene therapy research and development (R&D) from the public and private sectors is positively influencing the market growth. Along with this, the growing focus of venture capital firms, biotechnology companies, and pharmaceutical giants in the development and commercialization of therapies is acting as a growth-inducing factor. Additionally, the heightened funding by government and non-profit organizations for research and clinical trials to aid in overcoming the high costs associated with developing and scaling up advanced therapies is fueling the market growth.

  • Increasing Prevalence of Chronic Diseases and Genetic Disorders:

The rising prevalence of chronic diseases and genetic disorders is boosting the market growth. Along with this, the increasing geriatric population and incidences of lifestyle-related diseases, boosting the demand for innovative and effective treatments, is fostering the market growth. In line with this, cell and gene therapies offer potential cures and more effective treatments while managing symptoms is fueling the market growth. Moreover, the widespread inclusion of gene therapies in diseases such as cancer, heart disease, and diabetes to treat the conditions more fundamentally is bolstering the market growth. Additionally, the rising awareness among the public and medical community regarding the potential of gene therapies to provide significant improvements or cures, thereby propelling the demand for the treatments, is catalyzing the market growth.

Request for a sample copy of this report: https://www.imarcgroup.com/cell-gene-therapy-market/requestsample

Cell and Gene Therapy Market Report Segmentation:

Breakup By Therapy Type:

  • Cell Therapy
    • Stem Cell
      • Pluripotent Stem Cell
      • Cancer Stem Cell
      • Adult Stem Cell
    • Non-Stem Cell
      • T Cells
      • Natural Killer
      • Others
  • Gene Therapy

On the basis of therapy type, the market has been divided into cell therapy (stem cell (pluripotent stem cell, cancer stem cell, and adult stem cell) and non-stem cell (T cells, natural killer, and others)) and gene therapy.

Breakup By Indication:

  • Cardiovascular Disease
  • Oncology Disorder
  • Genetic Disorder
  • Infectious Disease
  • Neurological Disorder
  • Others

Oncology disorder accounted for the largest market share due to the high prevalence of cancer and the significant investment in developing targeted gene therapies that offer potentially curative treatments.

Breakup By Delivery Mode:

  • In-Vivo
  • Ex-Vivo

On the basis of delivery mode, the market has been divided into in-vivo and ex-vivo.

Breakup By End User:

  • Hospitals
  • Cancer Care Centers
  • Pharmaceutical & Biotechnology Companies
  • Others

Hospitals represented the largest segment due to their critical role in administering advanced therapies that require specialized equipment and highly trained medical staff.

Breakup By Region:

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

North America's dominance in the cell and gene therapy market is attributed to the region's advanced healthcare infrastructure, significant biotechnological research and development (R&D) expenditure, and supportive regulatory environment that accelerates the approval and adoption of innovative therapies.

Global Cell and Gene Therapy Market Trends:

The burgeoning integration of artificial intelligence (AI) and machine learning (ML) technologies to analyze vast amounts of genetic data more quickly and accurately, thereby significantly speeding up the identification of therapeutic targets and optimizing genetic modifications, is fueling the market growth. Moreover, the widespread adoption of predictive models and automation technologies to streamline production processes, predict outcomes, and ensure consistency and compliance with regulatory standards is enhancing market growth. Besides this, the development of non-viral delivery systems that are considered safer and potentially more effective than viral vectors and solve challenges related to immune response and integration of genetic material into patient genomes is catalyzing the market growth. 

Who are the key players operating in the industry?

The report covers the major market players including:

  • Amgen Inc.
  • Biogen
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb
  • Gilead Science
  • Kolon TissueGene Inc.
  • Orchard Therapeutics plc.
  • Pfizer Inc.
  • Renova Therapeutics
  • Spark Therapeutics, Inc.

Ask Analyst & Browse full report with TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=6964&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145